NCT00201864View on ClinicalTrials.gov

Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

June 30, 2012

Study Completion Date

February 28, 2014

Conditions
Breast Cancer
Interventions
DRUG

Exemestane

25 mg orally per day

DRUG

Fulvestrant

250 mg IM starting on Day 8 and then every 28 days.

Trial Locations (1)

43210

Ohio State University, Columbus

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Ohio State University Comprehensive Cancer Center

OTHER